不同他汀类药物治疗早发冠心病急性心肌梗死患者的疗效分析

Efficacy of Different Statin Therapy Early-onset Coronary Artery Disease Patients with Acute Myocardial Infarction

目的探究不同他汀类药物在早发冠心病急性心肌梗死治疗中的应用及其临床效果。方法选取在我院进行治疗的早发冠心病急性心肌梗死患者100例,分成对照组和观察组两组,每组50例。观察组患者应用瑞舒伐他汀进行治疗,而对照组患者应用阿托伐他汀进行治疗。药物用法及用量:瑞舒伐他汀,口服,每天10 mg;阿托伐他汀,口服,每天20 mg。治疗6个月后,观察两组患者血管内皮功能及心脏功能然后进行比较。结果治疗前,两组患者TC、LDL-C、hs-CRP、FMD以及LVEF相比无明显差异(P>0.05)。治疗后,两组患者TC、LDL-C、hs-CRP有明显差异,观察组比对照组明显降低,差异具有统计学意义(P<0.05);而FMD以及LVEF无明显差异(P>0.05)。两组患者不良心血管事件的发生率差异无统计学意义(P>0.05)。结论对于早发冠心病急性心肌梗死的患者来说,瑞舒伐他汀与阿托伐他汀均有较好的疗效。瑞舒伐他汀降脂效果更加明显。两种药物治疗后预后均较好。值得在临床推广使用。

Objective To explore the therapy effect of different statins in the treatment of patients with premature acute myocardial infarction. Methods Selected 100 cases of patients with premature acute myocardial infarction, and we divided them into the observation group and the control group, 50 cases in each group. The observation group was in the treatment of rosuvastatin, while the control group used atorvastatin. The drug usage and dosage： rosuvastatin, oral, 10 mg daily; atorvastatin, oral, 20 mg daily. After 6 months treatment, we detected vascular endothelial function and heart function, then we compared. Results Before treatment, the TC, LDL-C, hs-CRP, FMD and LVEF of the two groups showed no significant difference（P 〉0.05）. After treatment, the TC, LDL-C, hs-CRP of the two groups have significant difference, and the observation group was significantly lower than the control group, the difference was statistically significant（P〈0.05）; whereas there was no difference in FMD and LVEF（P〉0.05）. And the adverse cardiovascular events of the two groups have no significant difference（P〉0.05）. Conclusion For patients with early onset of acute myocardial infarction, the rosuvastatin and atorvastatin have a good effect. Rosuvastatin lowering effect is more pronounced. Both drugs have good treatment effect. It is worthy of promotion in clinical use.